Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vyne Therapeutics Inc (VYNE)

Vyne Therapeutics Inc (VYNE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Vyne Therapeutics Inc 685 ROUTE 202/206 SUITE 301 BRIDGEWATER NJ 08807 USA

www.vynetherapeutics.com Employees: 13 P: 800-775-7936

Sector:

Medical

INDUSTRY GROUPING:

Medical - Drugs

Description:

VYNE Therapeutics Inc. focuses on developing and commercializing therapeutics for dermatology. The company's product pipeline consist FMX103 and FCD105 which are in clinical stage. VYNE Therapeutics Inc., formerly known as Menlo Therapeutics Inc., is based in Bridgewater, New Jersey.

Key Statistics

Overview:

Market Capitalization, $K 12,502
Enterprise Value, $K -7,428
Shares Outstanding, K 33,286
Annual Sales, $ 500 K
Annual Net Income, $ -39,830 K
Last Quarter Sales, $ 170 K
Last Quarter Net Income, $ -7,280 K
EBIT, $ -37,300 K
EBITDA, $ -39,740 K
60-Month Beta 1.99
% of Insider Shareholders 3.03%
% of Institutional Shareholders 83.78%
Float, K 32,277
% Float 96.97%
Short Volume Ratio 0.29

Growth:

1-Year Return -84.35%
3-Year Return -87.65%
5-Year Return -99.71%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 99.58%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.17 on 11/06/25
Next Earnings Date 03/05/26
Earnings Per Share ttm -0.78
EPS Growth vs. Prev Qtr -30.77%
EPS Growth vs. Prev Year 41.38%
Annual Dividend & Yield 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-18 on 02/13/23

VYNE Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -80.84%
Return-on-Assets % -66.20%
Profit Margin % -7,966.00%
Debt/Equity 0.00
Price/Sales 26.91
Price/Cash Flow N/A
Price/Book 0.42
Book Value/Share 0.97
Interest Coverage -2.02
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar